300012 Centre Testing International Group
- 12.24
- +0.12+0.99%
Centre Testing International Group News
Huazue Testing (300012.SZ) plans to send 1 yuan to 10 shares to be exempted from interest on May 24
Huazu Testing (300012.SZ) announced that the company's 2023 equity distribution plan: every 10...
Huazue Testing (300012): Short-term performance is under pressure, and the layout of new fields accelerates long-term growth and can be expected
Incidents. The company discloses its 2023 annual report and 2024 quarterly report. 1) In 2023, the company achieved operating income of 5.605 billion yuan, +9.24% year-on-year, and net profit to mother of 910 million yuan, +0.83% year-on-year
Express News | Huazu Testing won the bid for the 2024 Qinghai Product Quality Supervision and Random Inspection and Risk Monitoring Project
CTI Huazue certification helped complete the first batch of 10,000 tons of carbon emission reduction transactions
SHENZHEN, April 29, 2024/PRNewswire/ -- In March 2024, Huace Certification Co., Ltd. (CTI Huace Certification), a wholly-owned subsidiary of Huazue Testing and Certification Group Co., Ltd. (CTI Huazue Certification for short), acted as the auditor of the VCS project and completed the approval and certification of the world's first VCS project for recycling waste electrical and electronic products. The project was successfully registered with VCS and was first issued for emission reduction on April 2, 2024. Senior professional, CTI Huaxue certification strives for excellence, Shengtang
Express News | The concept of computing power continues to ferment, and many leading telecommunications companies have received intensive research from institutions
Southwest Securities released a research report on April 25 stating that it gave Huazue Testing (300012.SZ) a holding rating. The main reasons for the rating include: 1) steady development in traditional fields, industrial testing and consumer goods testi
Southwest Securities released a research report on April 25 stating that it gave Huazue Testing (300012.SZ) a holding rating. The main reasons for the rating include: 1) steady development in traditional fields, industrial testing and consumer goods testing sectors driving the company's revenue growth; 2) declining gross margin in life sciences, consumer goods testing, trade assurance, medicine and other sectors, putting pressure on the company's comprehensive gross margin net margin; 3) Continued investment in the strategic circuit to create a second growth curve. (Mainichi Keizai Shimbun)
Huazu Testing (300012): The pharmaceutical sector is under short-term pressure, and Sanpu's orders have entered the fulfillment period
Core view: Performance is affected by the pharmaceutical sector, waiting for 24 years to recover. The company released an annual report and quarterly report, and achieved operating revenue of 5.605 billion yuan in 23, +9.24% year on year, of which overseas revenue was 345 million yuan, +2 year on year
Express News | Maoming Guangzhou and Port built the country's first general terminal to pass the “carbon neutrality” certification
Centre Testing International Buys Back Shares for 72 Million Yuan
Centre Testing International Group (SHE:300012) repurchased shares for 71.5 million yuan, the company said in a Tuesday filing on the Shenzhen Stock Exchange. The Chinese testing laboratory company bo
Huatest Testing (300012): Revenue increased 6.7% year-on-year in the first quarter of 2024, and the pharmaceutical business is under pressure in the short term
In 2023, revenue increased 9.24% year over year, and net profit to mother increased 0.83% year over year. The company achieved operating income of 5.605 billion yuan in 2023, an increase of 9.24% over the previous year; net profit to mother was 910 million yuan, same as
Huatest Testing (300012): Medicine is under short-term pressure and is optimistic that leading testing companies will continue to grow steadily in the medium to long term
The 2023 performance increased 0.8% year on year and is close to the forecast center. According to the company's 2023 annual report, the pharmaceutical and medical sector is under pressure to achieve revenue of 5.6 billion yuan, an increase of 9.2% over the previous year, and net profit to mother of 9.1 billion yuan, an increase of 9.1 billion yuan over the previous year
Huazue Testing (300012.SZ): According to the schedule of the strong inspection work in the Qiantang New Area of Hangzhou, Hangzhou Huazue completed the mandatory inspection work of gas meters in a timely manner, with quality and quantity
Gelonghui, April 22 | Huazue Testing (300012.SZ) said on the investor interactive platform that Hangzhou Huace Testing Technology Co., Ltd., a subsidiary of Huazue, has obtained special authorization for compulsory gas meter inspection in accordance with the law, and is the first third party in Zhejiang Province to obtain a special authorized agency for compulsory inspection of civilian gas meters. According to the schedule for the intensive inspection work in the Qiantang New Area of Hangzhou, Hangzhou Huazou completed the mandatory inspection work of gas meters in a timely manner while maintaining quality and quantity. Measurement, calibration and conformity assessment are one of Huazu's important service capabilities. Doing a good job in measuring people's livelihood and ensuring accurate measurement values are important tasks to ensure market fairness and achieve safe consumption.
Huatest Testing (300012): Short-term pharmaceutical and medical testing companies under pressure have outstanding long-term competitiveness
The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 5.605 billion yuan, yoy +9.24%, net profit to mother of 910 million yuan, yoy +0.83%, gross profit margin
Earnings Miss: Centre Testing International Group Co. Ltd. Missed EPS By 25% And Analysts Are Revising Their Forecasts
The analysts might have been a bit too bullish on Centre Testing International Group Co. Ltd. (SZSE:300012), given that the company fell short of expectations when it released its quarterly results la
Huazu Testing (300012): The pharmaceutical sector is under short-term pressure and long-term development is improving
Guide to this report: The company's 2023 performance is in line with expectations. Industrial and consumer goods testing is growing well. The pharmaceutical and medical sector is under pressure in the short term and continues to invest in the strategic circuit, which is expected to start new growth. Key investment points: Maintain an increase in holdings rating. Taking into account medicine
Huatest Testing (300012): Short-term pressure on the pharmaceutical sector, marginal improvement in Q1 comprehensive gross margin
Core view In 2023, the company achieved revenue of 5.605 billion yuan, a year-on-year increase of 9.24%, and net profit to mother of 910 million yuan, an increase of 0.83% over the previous forecast. The actual performance was at the center of the previous forecast. By sector, consumer goods
China Testing: The future will seize opportunities in the era of rapid growth of the low-altitude economy
Huazue Testing said on the interactive platform that Huazue had an early presence in the aviation service field. As early as 2019, it obtained COMAC's qualified supplier certificate, and is a third-party testing laboratory approved by COMAC and China Commercial Development. Huazu has a forward-looking layout in terms of testing capacity, site capacity, talent team, scientific research and development. It has successively established mature laboratories and testing capabilities in aviation and low-altitude economic industrial clusters such as Shenzhen, Guangzhou, Shanghai, Suzhou, Tianjin, Wuhan, Chongqing, Chengdu, Xi'an, and Shenyang, which can provide civil manned and unmanned aerial vehicles, including environmental reliability tests, electromagnetic compatibility tests, and hazardous substance testing
Guolian Securities released a research report on April 19 stating that the target price for HuaTest Testing (300012.SZ) was given a purchase rating of 27.58 yuan. The main reasons for the rating include: 1) all major sectors grew in 23, and medical testin
Guolian Securities released a research report on April 19 stating that the target price for HuaTest Testing (300012.SZ) was given a purchase rating of 27.58 yuan. The main reasons for the rating include: 1) all major sectors grew in 23, and medical testing is still under pressure; 2) the year-on-year growth rate of 24Q1 slowed under the high base of 23Q1; 3) the company seizes new track opportunities and actively lays out the field of aviation testing. (Mainichi Keizai Shimbun)
Fangzheng Securities: Demand for testing services expands and the low-altitude economy is expected to contribute to new growth
Economic and social development has led to an expansion in demand for testing services, the policy side is gradually liberalizing the scope of third-party testing services, and the logic of sustainable industry growth continues to be interpreted.
Huazue Testing (300012): Profit margins narrowed year-on-year due to structural factors
Net profit to mother in 2023 was +1% year over year, profit forecast was lowered and target price Huazue Testing released an annual report. In 2023, it achieved revenue of 5.61 billion yuan (+9% year over year) and net profit to mother of 910 million yuan (+1% year over year), not net
Analysis
Price Target
No Data
